Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

SAN FRANCISCO, July 16 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed a private placement of shares of its common stock and warrants to purchase additional common stock for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital Inc., a FINRA member broker dealer acted as the exclusive placement agent for the transaction.

"We are extremely pleased to have the completed this financing," said Joshua Kazam, Chief Executive Officer, "which we believe will provide us with sufficient capital to complete our Phase 2 clinical study of CD-NP in acute heart failure patients with mild to moderate renal insufficiency."

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. Nile has agreed to file a registration statement covering the resale of the shares issued in the private placement, including the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas o
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...o Speak at Economic Club of Canada , ...009 -- Ambassador to Speak at Economic Club of Can... for International Investment, and Chairman and CE...phy of David Appia go to www.investinfrance.org ....t with press to discuss recent pro-business initia...
(Date:11/25/2009)...stCall/--ArdeaBiosciences,Inc.(Nasdaq: RDEA )annou...efexecutiveofficer,willpresentatthePiperJaffray21s...lsareasfollows:,PiperJaffray21stAnnualHealthCareC....EasternTime,Location:TheNewYorkPalaceHotel,NewYor...reye/,target=,_blank,title=,http://www.corporate-...
(Date:11/24/2009)...wire/--TwomoreprestigiousuniversitieshavejoinedBio...reerssiteforlifescienceprofessionals. ,, Northw...ard,joining28othermajorlifesciencetrainingInstitut...isonlyforpost-graduatesinthelifesciences.Whilether...BioCareerCenteristheonlyonethatserveslifesciencepo...
(Date:11/24/2009)...RNewswire-FirstCall/--deCODE,genetics,Inc.(Nasdaq:...ay"motionsbytheU.S.BankruptcyCourtfortheDistrictof...davoluntarypetitionfor,reliefunderChapter11oftheUn...,, TheordersissuedbytheBankruptcyCourtallowthec...ter11proceedings.Inparticular,the,companyreceivedi...
Breaking Biology Technology:French Ambassador for International Investment to Visit Toronto December 11 2Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
...., Sept. 16 Barr,Pharmaceuticals, Inc. (NYSE: BR...ratories, Inc., received final approval from the U...e and market a generic version of Ortho,McNeil Jan...tended release,capsules), eq. to 8 mg, 16 mg and 2...pany to file an Abbreviated New Drug Application (...
...., Sept. 16 ,( http://www.amdl.com ) AMDL, Inc. (A...l company with major operations in China and the U...s of a $2,510,000 private placement,offering of 10...offering,were Jesup & Lamont Securities Corporatio...er, President and CEO of AMDL, Inc., said, "This f...
...ss., Sept. 16 Peptimmune, Inc. a privately,held b...eph Kovalchin will,make a poster presentation titl...irst-in-Man Single Ascending Dose Study of Peptide...clerosis " on Thursday, September 18th from,3:30 -... Congres de,Montreal, Canada at the World Congress...
Other Biology Technology:Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules 2Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules 3Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules 4Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules 5AMDL, Inc. Closes Private Placement of Convertible Notes 2AMDL, Inc. Closes Private Placement of Convertible Notes 3AMDL, Inc. Closes Private Placement of Convertible Notes 4Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis 2
(Date:11/24/2009)...n Spanish . , The presence of increased bod... substances in the blood, hinders the loss and mai...oject of the University of Navarra conducted by Es...of Pharmacy. , The project, entitled "A nutrigen...trol of body weight and inflammation," examines ho...
(Date:11/23/2009)... - The time of day matters to forest trees dealing...y a research team led by Professor Malcolm Campbel...pal for research and colleagues in the department ...us. , Capitalizing on their previous work to d...team examined how poplar trees use their 45,000 ge...
(Date:11/23/2009)...dy provides "incontrovertible evidence" that the v...matra about 73,000 years ago deforested much of ce...researchers report. , The volcano ejected an est...here, leaving a crater (now the world,s largest vo...lometers wide. Ash from the event has been found i...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2Time of day matters to thirsty trees, U of T researcher discovers 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2July 2009 Mayo Clinic Womens HealthSource Highlights Food Storage Safety Energy Therapies and Vitamins and Minerals 4766 1July 2009 Mayo Clinic Womens HealthSource Highlights Food Storage Safety Energy Therapies and Vitamins and Minerals 4766 2July 2009 Mayo Clinic Womens HealthSource Highlights Food Storage Safety Energy Therapies and Vitamins and Minerals 4766 3July 2009 Mayo Clinic Womens HealthSource Highlights Food Storage Safety Energy Therapies and Vitamins and Minerals 4766 4July 2009 Mayo Clinic Womens HealthSource Highlights Food Storage Safety Energy Therapies and Vitamins and Minerals 4766 5Mass General based research center will investigate why immune system fails to control hepatitis C 52435 1Mass General based research center will investigate why immune system fails to control hepatitis C 52435 2Stop and smell the flowers the scent really can soothe stress 9324 1
...NeuralIQ, a developer of,cyber intelligence tools ...nsion of its global leadership team, headed by the...fficer., Blanks, former Executive Vice President ...t business unit, assumes the helm of NeuralIQ as t...nce and paradigm-shifting,security technology in r...
... Though skin cancer is deadly to male fish, it al...e from attractive natural markings that lure femal... of the National Academy of Sciences this week sh...rdtail fish because of its beneficial role in sexu...Fernandez and Molly Morris studied three populatio...
...nal Science Foundation,s Expeditions in Computing ...rogramming Project, a collaborative effort by rese...and the University of Washington to establish a fu...lar and chemical systems based on the principles o...molecular programs, are collections of molecules t...
Other Biology News:NeuralIQ Expands Global Leadership Team, Names Donnie Blanks CEO 2NeuralIQ Expands Global Leadership Team, Names Donnie Blanks CEO 3Fish cancer gene linked to pigment pattern that attracts mates 2Caltech researchers awarded $10M for molecular programming project 2
Anti-Interferon-beta (IFNb) Monoclonal Antibody, Unconjugated from CHEMICON
...se in Refrigerated Vapor Trap Models RVT100, RVT40...(UVS) Models UVS400, UVS400A and UVS800DDA., A no...e polymer suitable for use for temperatures rangin...excellent thermal stability and does not evaporate...
Acetate Plate Sealers from Thermo Scientific
...ature of proteomics demands the detection of very ...of the AXIMA-CFRplus with improved resolution (20,...increased confidence in protein identification. Th...hanced sensitivity, automated sample target handli...
Biology Products: